Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05904470 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
A Phase 2 study of Hepatitis C and Hepatitis C, Chronic, sponsored by Atea Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 275
- Enrollment target
- 20
- Study locations
NCT05904470: Completed Phase 2 study of Hepatitis C and Hepatitis C, Chronic, sponsored by Atea Pharmaceuticals.
NCT05904470 is a Phase 2 study of Hepatitis C and Hepatitis C, Chronic that has completed, run by Atea Pharmaceuticals. The registered enrollment target is 275 participants, below the 1,888-participant average among 106 other Hepatitis C trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05904470, a Phase 2 study of Hepatitis C and Hepatitis C, Chronic, has completed, sponsored by Atea Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 275 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.
Primary Outcome
SVR12 defined as plasma hepatitis C virus (HCV) RNA less than the lower limit of quantitation (\<LLOQ) at 12 weeks post-treatment
Conditions Studied
Interventions
- DRUG Bemnifosbuvir
- DRUG Ruzasvir
Study Locations (20)
São Paulo
- Atea Study Site - Botucatu
- Atea Study Site - Ijuí
- Atea Study Site - São José do Rio Preto
- Atea Study Site - São Paulo
- Atea Study Site - São Paulo
- Atea Study Site - Sorocaba
Rio Grande do Sul
- Atea Study Site - Porto Alegre
- Atea Study Site - Porto Alegre
Gujarat
- Atea Study Site - Rajkot
- Atea Study Site - Surat
Texas
- Atea Study Site - San Antonio
Amazonas
- Atea Study Site - Manaus
Estado de Bahia
- Atea Study Site - Salvador
Federal District
- Atea Study Site - Brasília
Rio Do Janeiro
- Atea Study Site - Rio de Janeiro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2023-05-30 |
| Est. Completion | 2025-01-28 |
| Phase | Phase 2 |
What the finished NCT05904470 record still lists
NCT05904470 is an interventional study that assigns participants to a tested intervention. The registered 275 participants enrollment target is mid-sized for trials with a published cap, below the 1,888-participant average among 106 other Hepatitis C trials with a reported enrollment target (85% lower).
The record links to 5 conditions, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Bemnifosbuvir is the first listed.
NCT05904470 names 20 study sites across 13 states, led by São Paulo, Rio Grande do Sul, Gujarat.
Frequently Asked Questions
What is clinical trial NCT05904470 about?
NCT05904470 is a clinical study titled "A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV". This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.
What is the current status of trial NCT05904470?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 275 participants. The study started on 2023-05-30. Estimated completion is 2025-01-28.
What conditions does trial NCT05904470 study?
This clinical trial studies the following conditions: Hepatitis C, Hepatitis C, Chronic, HCV, Chronic Hepatitis C Virus, Hepatic Cirrhosis.
What interventions are being tested in trial NCT05904470?
The interventions under investigation include: Bemnifosbuvir (DRUG), Ruzasvir (DRUG).
Who is sponsoring clinical trial NCT05904470?
This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05904470 being conducted?
This trial has 20 study locations across Texas, Amazonas, Estado de Bahia, Federal District, Rio Do Janeiro. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05904470's enrollment target sits among peer trials
275 39th of 106 higher than 68 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Expanding the Pool in Orthotopic Heart Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
COMPLETED · Phase 2
-
Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C
COMPLETED · Phase 2
-
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
COMPLETED · Phase 2
-
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269190 · 275 participants · NA
Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery
- NCT01900132 · 275 participants · NA
Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers
- NCT04104776 · 275 participants · Phase 1
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- NCT04765150 · 275 participants
Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI